The Drug Enforcement Administration this week proposed reducing aggregate production quotas for five opioid controlled substances in 2020. The proposal would reduce the amounts of fentanyl by 31%, hydrocodone by 19%, hydromorphone by 25%, oxycodone by 9% and oxymorphone by 55%. The five opioid substances were subject to special scrutiny following the enactment last year of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, which requires DEA to estimate the amount of diversion of the covered substance that occurs in the United States and make appropriate quota reductions. DEA will accept comments on the 2020 proposed aggregate production quotas, which address more than 250 Schedule I and II controlled substances, through Oct. 15.

Related News Articles

Headline
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected…
Headline
The Centers for Disease Control and Prevention today released updated guidelines for clinicians prescribing opioids to outpatients for short- or long-term…
Headline
In this episode – part four of AHA’s five-part series on opioid stewardship – Marie Cleary-Fishman, AHA’s vice president of clinical quality, is joined once…
Headline
In part three of AHA’s five-part series on opioid stewardship, Marie Cleary-Fishman, AHA’s vice president of clinical quality, speaks with Holly Geyer, M.D.,…
Headline
The Food and Drug Administration approved the second generic naloxone nasal spray, an emergency treatment for known or suspected opioid overdose. The…
Headline
Organizations can apply through July 29 for a portion of $10 million in funding to expand access to medication-assisted treatment for opioid use disorder in…